Innate Pharma (IPHA) Establishes New At-The-Market Program on Nasdaq
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
April 26, 2023 4:50 PM EDTMARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (SEC) relating to a new At-The-Market (ATM) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75 million of American Depositary Shares (ADS), each ADS representing one ordinary share of Innate, from time to time in sales deemed to be an at the market offering... More



